Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caribou Biosciences filings document a clinical-stage CRISPR genome-editing biopharmaceutical company focused on allogeneic CAR-T therapies. Recent 8-K reports furnish quarterly and annual financial results, cash and operating-plan disclosures, business updates, and Regulation FD disclosures covering vispa-cel and CB-011 clinical and FDA-related developments.
Proxy materials describe annual meeting matters, board elections, auditor ratification, and proposed charter governance changes for the Delaware corporation. Other event filings record public-company status matters, including Nasdaq bid-price compliance notices and product-candidate regulatory designations.
Caribou Biosciences filed a notice relating to the proposed sale of 6,938 common shares tied to the vesting of restricted stock units on 02/20/2026.
The shares were granted as part of the issuer's equity compensation plan and are reported through a Form 144 filing for proposed resale on the NASDAQ.
Caribou Biosciences, Inc. submitted a Rule 144 notice relating to 6,938 common shares associated with vesting restricted stock units granted under its equity compensation plan. The filing lists dates 02/20/2026 (vesting/grant) and 02/24/2026 (filing) and identifies NASDAQ as the market.
Timothy Kelly reported proposed sales of common stock via a Form 144. The filing lists 6228 shares of restricted common stock dated 02/20/2026 and shows 3147 common shares sold during the past three months on 02/24/2026 with an amount of 6162.14. The transaction is reported in connection with Nasdaq-listed securities.
Caribou Biosciences Chief Technology Officer Timothy P. Kelly reported a mix of equity awards and a small tax-related share sale. He received 45,000 restricted stock units that vest in four equal annual installments beginning on February 20, 2027, settling in stock within 30 days after each vesting date.
He was also granted an option to buy 202,500 shares of common stock, vesting monthly so the option is fully vested by February 20, 2030. Separately, 3,147 shares of common stock were sold at $1.96 per share under a mandatory sell‑to‑cover policy to satisfy tax withholding when previously granted RSUs vested, and this did not represent a discretionary trade. After these transactions, Kelly directly holds 79,353 shares of common stock and 202,500 option shares.
Caribou Biosciences Chief Legal Officer Barbara G. McClung reported both equity grants and a small share sale. She received a grant of options to purchase 202,500 shares of common stock and a separate grant of 45,000 restricted stock units, both awarded on February 20, 2026.
The options vest in equal monthly installments over 48 months until February 20, 2030, and the RSUs vest in four equal annual installments beginning February 20, 2027, contingent on continued service. On February 24, 2026, 6,938 shares were sold at $1.96 per share solely to cover tax withholding on previously vested RSUs under an existing Rule 10b5-1 sell-to-cover plan, leaving her with 481,564 common shares directly owned.
Caribou Biosciences Chief Business Officer Ruhi Ahmad Khan reported a mix of equity grants and a small tax-related share sale. On February 24, 2026, Khan sold 6,938 shares of common stock at $1.96 per share in an open-market transaction, leaving 104,998 shares held directly. A footnote explains this was a sell-to-cover trade executed under a Rule 10b5-1 plan solely to satisfy tax withholding on vesting RSUs, not a discretionary sale.
On February 20, 2026, Khan received a grant of 45,000 restricted stock units that vest in four equal annual installments beginning on February 20, 2027, with shares delivered within 30 days after each vesting date. On the same date, Khan was granted options for 202,500 shares of common stock, vesting monthly over 48 months so that the option is fully vested by February 20, 2030, contingent on continued service.
Caribou Biosciences Chief Medical Officer Tina M. Albertson reported a mix of equity grants and a small tax-related sale. She received 55,000 shares of common stock as restricted stock units that vest annually over four years starting on February 20, 2027. She was also granted an option for 247,500 shares of common stock, vesting monthly so that it is fully vested by February 20, 2030.
Separately, 1,066 common shares were sold at $1.96 per share in a sell-to-cover transaction to satisfy tax withholding on previously vested RSUs under a pre-established Rule 10b5-1 trading plan. After these transactions, she directly holds 68,523 common shares.
Caribou Biosciences director Zheng Ran received an option grant for 45,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory equity award rather than a market purchase.
According to the vesting terms, one-twelfth of the option shares vest on each monthly anniversary of the February 20, 2026 grant date, so the award will be fully vested by February 20, 2027, as long as Zheng Ran continues providing services to Caribou Biosciences through each vesting date.
Caribou Biosciences, Inc. reported that director Nancy Whiting received a grant of options to purchase 45,000 shares of common stock. The options have an exercise price of $0.00 per share, representing a compensatory award rather than a cash purchase.
According to the terms, one-twelfth of the option grant vests on each monthly anniversary of the grant date and will be fully vested by February 20, 2027, as long as she continues providing service to the company through each vesting date.
Sacks Natalie reported acquisition or exercise transactions in this Form 4 filing.
Caribou Biosciences, Inc. reported that director Natalie Sacks received an option grant to purchase 45,000 shares of common stock. The option was awarded at a price of $0.00 per share, reflecting a no-cost equity award rather than an open-market purchase.
According to the vesting terms, one-twelfth of the option shares will vest on each monthly anniversary of the grant date, so the award will be fully vested by February 20, 2027, assuming she continues providing service to the company through each vesting date.